Permira acquired a controlling stake in Kedrion from the founding Marcucci family and existing institutional investors FSI and CDP Equity. The transaction was structured as a partnership where the Marcucci family, FSI, and CDP Equity reinvested a significant minority stake to maintain the group's Italian heritage and operational continuity. The deal was contingent on the simultaneous acquisition of BPL to create a unified global platform. This allowed Kedrion to secure its supply chain and significantly expand its US and international footprint while transitioning from a family-run business to a private equity-backed global player.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.